Age-dependent hematologic toxicity profiles and prognostic serologic markers in postoperative radiochemotherapy treatment for uterine cervical cancer

• Verfasst von: Meixner, Eva [VerfasserIn]
• Verfasst von: Hoeltgen, Line [VerfasserIn]
• Verfasst von: Hoegen-Saßmannshausen, Philipp [VerfasserIn]
• Verfasst von: König, Laila [VerfasserIn]
• Verfasst von: Arians, Nathalie [VerfasserIn]
• Verfasst von: Michel, Laura L. [VerfasserIn]
• Verfasst von: Smetanay, Katharina [VerfasserIn]
• Verfasst von: Fremd, Carlo [VerfasserIn]
• Verfasst von: Schneeweiss, Andreas [VerfasserIn]
• Verfasst von: Debus, Jürgen [VerfasserIn]
• Verfasst von: Hörner-Rieber, Juliane [VerfasserIn]
• Titel: Age-dependent hematologic toxicity profiles and prognostic serologic markers in postoperative radiochemotherapy treatment for uterine cervical cancer
• Verf.angabe: Eva Meixner, MD, Line Hoeltgen, MD, Philipp Hoegen, MD, Laila König, MD, Nathalie Arians, MD, Laura L. Michel, MD, Katharina Smetanay, MD, Carlo Fremd, MD, Andreas Schneeweiss, MD, Jürgen Debus, MD, PhD, and Juliane Hörner-Rieber, MD
• E-Jahr: 2022
• Jahr: August 10, 2022
• Umfang: 12 S.
• Fussnoten: Gesehen am 14.02.2023
• Titel Quelle: Enthalten in: Technology in cancer research & treatment
• Ort Quelle: Thousand Oaks, CA : Sage Publishing, 2002
• Jahr Quelle: 2022
• Band/Heft Quelle: 21(2022), Artikel-ID 15330338221118188, Seite 1-12
• ISSN Quelle: 1533-0338
• DOI: doi:10.1177/15330338221118188
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1835122558

Abstract

Introduction: In the adjuvant setting for cervical cancer, classical risk factors for postoperative radiochemotherapy have been established. However, data on laboratory changes during therapy and the prognostic value of serological markers are limited and further knowledge is needed to optimize the toxic trimodal regimen. Methods: We retrospectively identified 69 women who underwent weekly postoperative radiochemotherapy with 40?mg/m2 of cisplatin for cervical cancer between 2010 and 2021 at a single center. Laboratory parameters were recorded before, at each cycle and after radiochemotherapy. Kaplan-Meier and log-rank analyses were used to calculate and compare survival, groups were compared using the Mann?Whitney U, ?2, and variance tests. Results: With a median follow-up of 17.7 months, the 1- and 5-year local control rates were 94.0% and 73.7%, respectively, with significantly better rates for more chemotherapy cycles and negative resection margins. Only 68.1% of patients completed all cycles. The most common reasons for early discontinuation were persistent asymptomatic leukopenia in women aged ≤ 50 years, and limiting infections in women aged > 50 years. Leukopenia was more likely to occur after the third cycle. Significantly worse survival was observed for post-radiochemotherapy elevated C-reactive-protein and lactate dehydrogenase levels, low pre-radiochemotherapy nutritional index, and raised C-reactive-protein-levels; the latter were also predictable for local control. The Glasgow prognostic score did not reliably predict survival. Conclusion: Incomplete application of simultaneous chemotherapy leads to inferior local control, and age-dependent limiting factors should be identified at an early stage. In addition to classical risk factors, serological markers (C-reactive-protein, lactate dehydrogenase, nutritional index) show prognostic significance.